Know Cancer

or
forgot password

A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Head and Neck Cancer, Oropharyngeal Cancer

Thank you

Trial Information

A Pilot Trial of Image-Guided Adaptive Radiotherapy for Head and Neck Cancer


The Study Scans and Tests:

IMRT is a type of 3-dimensional (3-D) radiation therapy that can focus radiation beams
directly on the tumor itself. In this study, the IMRT is given using a standard radiation
machine (ExaCTâ„¢ machine) that has a CT scanner attached to it. This machine is commonly
used in patients with head and neck cancer. It gives the same radiation treatment as most
of the other machines at M. D. Anderson. However, in addition to giving radiation
treatments, it can also perform CT scans while the patient is in the same position on the
treatment table, before the radiation therapy is given.

For this study, your standard of care daily CT scans will be used to help researchers adjust
participants' radiation therapy, if necessary, on a weekly basis. In particular, the
changes in normal tissue that are being studied are any changes in the salivary glands. An
additional research related MRI scan will also be performed in this study, but the MRI scan
will not be used to adjust participants' therapy. Researchers want to learn if MRI scanning
may be able to help doctors in the future to adjust someone's treatment based on changes in
a tumor (its features and size) in response to radiation.

Enrollment in the Study:

If you agree to take part in this study, you will receive IMRT according to the standard
schedule (over 6 - 7 weeks). You will sign a separate consent form for the IMRT, and the
procedure and its risks will be explained to you at that time.

CT Scans:

During this study, you will have a standard of care CT scan right before each IMRT treatment
(over a 6-7 week period of time, depending on the exact schedule your doctor decides would
be best for your treatment). These CT scans are standard of care, are used to make sure
your treatment is being aimed properly, and would be performed whether you are participating
on this trial or not. Once you are set up on the treatment table and are ready for
radiation therapy, the table will be turned around and the CT scan will be performed. After
the CT scan, which should take about 5-8 minutes, the table will be turned back around to
the original position and the radiation treatment will be given to you. In total, about
30-33 CT scans will be performed for this study, depending on the exact number of treatments
the doctor decides would be best for your therapy.

Routine MRI Scans:

Routine MRI scans of your head and neck will be performed before treatment (at Week 1) and
after treatment (sometime during Weeks 12-14). These scans may be used for routine
treatment planning and checking the status of the disease.

Study-Related MRI Scan:

An additional MRI scan will be done halfway through treatment (during Week 3). This MRI
scan will be used to help researchers see if MRI scanning may be able to help doctors in the
future to adjust someone's treatment based on changes in a tumor (its features and size) in
response to radiation. In 15 participants, a repeat baseline study-related MRI scan will be
done 48 hours to 1 week following the first routine MRI scan.

Modified Barium Swallow:

Your swallowing function will be tested with a special type of x-ray called a modified
barium swallow (MBS). During the test, you will eat and drink foods and liquids mixed with
a "contrast" chemical called barium that will make your throat more visible in the x-rays.
A special x-ray tube will be connected to a television screen to allow the doctor to watch
the foods and liquids pass from your mouth and down your throat.

MBS will be performed before you start radiation therapy, 4-6 months after the end of
radiation therapy, and during your routine follow-up visits, 12 months (plus or minus 2
months), and 24 months (plus or minus 3 months).

Saliva Testing:

One reason IMRT is being used is to try to protect your parotid glands (the largest of the
salivary glands) from receiving too much radiation. To check this, a study-related saliva
test will be done. For this test, the amount of saliva your parotid glands create will be
measured before treatment (within 7 days before Week 1) and at the last week of treatment
(during Week 6 or 7). Do not eat or drink anything, or put anything in your mouth, for 1
hour before the saliva collections. You will be asked to let your saliva collect in your
mouth for 5 minutes and then spit into a cup. After that, you will be given a mild citric
acid solution (like lemon juice) to put in your mouth. You will let the saliva collect in
your mouth for 5 minutes and then spit in a cup. Saliva testing will be performed under a
separate protocol (LAB07-0050).

Length of Study:

If the disease gets worse or intolerable side effects occur, you will be taken off this
study.

Follow-Up Visits:

At some time between Weeks 22 and 24, then every 3-4 months for up to 2 years after the last
IMRT, you will return for follow-up visits. The amount of saliva your parotid glands create
will be measured 6 weeks after radiation therapy, 4-6 months after radiation therapy, 1 year
(plus or minus 2 months) after radiation therapy, and 2 years (plus or minus 3 months) after
radiation therapy.

This is an investigational study. The ExaCTâ„¢ machine is FDA approved for use in IMRT in
patients with head and neck cancer. Researchers are using this standard of care CT Scan for
routine quality assurance to make sure your treatment is given correctly. Up to 45
patients will take part in this study. All will be enrolled at M. D. Anderson.


Inclusion Criteria:



1. Patients older than 18 years of age with histologically proven squamous cell
carcinoma of the oropharynx, dispositioned to receive definitive radiotherapy for
intact primary tumor.

2. Stage III, IVa, or IVb disease as defined by American Joint Committee on Cancer
(AJCC) cancer staging criteria.

3. ECOG performance status 0-2.

Exclusion Criteria:

1. Patients who have undergone definitive resection of the primary tumor.

2. Prior cancer diagnosis, except appropriately treated localized epithelial skin cancer
or cervical cancer.

3. Prior radiation therapy to the head and neck region.

4. Patients unable or unwilling to give written, informed consent or to undergo MRI
imaging.

5. Women of childbearing potential (A woman of child-bearing potential is a sexually
mature woman who has not undergone a hysterectomy or who has not been naturally
postmenopausal for at least 24 consecutive months [i.e., who has had menses at any
time in the preceding 24 consecutive months]) and male participants must practice
effective contraception (oral, injectable, or implantable hormonal contraceptive;
tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or
vasectomized partner) throughout the study

6. Patients unable to tolerate DW-MRI or DCE-MRI or having an estimated GFR < 60
ml/min/1.73m2.

7. Patients who have had prior chemotherapy.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Comparison of dosimetry with head and neck (H&N) adaptive radiotherapy (ART) planning relative to standard intensity-modulated radiation therapy (IMRT) planning

Outcome Time Frame:

Baseline by standard IMRT plan and adaptive dosing by ART plan evaluated at end of ART at week 6-7.

Safety Issue:

No

Principal Investigator

Adam Garden, MD, BA

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

2006-0947

NCT ID:

NCT00490282

Start Date:

June 2007

Completion Date:

Related Keywords:

  • Head and Neck Cancer
  • Oropharyngeal Cancer
  • Head and Neck Cancer
  • Oropharyngeal Cancer
  • Adaptive Radiotherapy
  • Intensity Modulated Radiation Therapy
  • IMRT
  • ART
  • Head and Neck Neoplasms
  • Oropharyngeal Neoplasms

Name

Location

UT MD Anderson Cancer CenterHouston, Texas  77030